FDA Accepts Priority Review Of Biologics License Application For ltragenyx Pharmaceutical's DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical, Inc. +3.98% Pre
Ultragenyx Pharmaceutical, Inc. RARE | 24.57 24.57 | +3.98% 0.00% Pre |
If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa
